Subscribe
lukassek-shutterstock-com-2
Lukassek / Shutterstock.com
19 May 2016Europe

Bayer and ERS enter CRISPR patent licensing agreement

Bayer and ERS Genomics have signed a patent licensing agreement which gives Bayer access to ERS’s CRISPR/Cas9 genome-editing patents.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Big Pharma
PeriRx’s breach of licensing contract suit can’t prevail
13 January 2022   Oral diagnostics company PeriRx has lost a patent licensing suit against the University of California and research company RNAmeTRIX, claiming that they had breached sublicensing agreements.


Editor's picks

LSPN: In-house ‘chess game’ is the same, but the rules have changed
Americas
LSPN: In-house ‘chess game’ is the same, but the rules have changed
9 May 2025

Editor's picks

Americas
LSPN: In-house ‘chess game’ is the same, but the rules have changed
9 May 2025

More on this story

Big Pharma
PeriRx’s breach of licensing contract suit can’t prevail
13 January 2022   Oral diagnostics company PeriRx has lost a patent licensing suit against the University of California and research company RNAmeTRIX, claiming that they had breached sublicensing agreements.

More on this story

Big Pharma
PeriRx’s breach of licensing contract suit can’t prevail
13 January 2022   Oral diagnostics company PeriRx has lost a patent licensing suit against the University of California and research company RNAmeTRIX, claiming that they had breached sublicensing agreements.

More features

LSPN: In-house ‘chess game’ is the same, but the rules have changed
Life sciences leaders recognised at LSPN Awards USA 2025
UK-India trade deal is ‘a missed opportunity for UK pharma’, says industry body
LSPN: Counsel grapple with AI’s impact on training and critical thinking
'Nothing can stand in the way of our work': Ukraine resumes IP system
LSPN: Trump's policy storm causing chaos and confusion
Taylor Wessing expands in Europe with Paris team
LSPN: Using ‘the patentee’s friend’ in Section 112 claims